Milademetan - Daiichi Sankyo

Drug Profile

Milademetan - Daiichi Sankyo

Alternative Names: DS-3032; DS3032b

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Daiichi Sankyo Inc; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cyclohexanes; Indoles; Pyrrolidines
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Lymphoma; Multiple myeloma; Solid tumours

Most Recent Events

  • 14 Jun 2018 Preclinical trials in Acute myeloid leukaemia (Combination therapy) in Japan (IV)
  • 14 Jun 2018 Preclinical trials in Acute myeloid leukaemia (Combination therapy) in Japan (SC)
  • 14 Jun 2018 Pharmacodynamics data frompreclinical studies in Acute myeloid leukemia presented at the 23rd Congress of the European Haematology Association (EHA-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top